EFTA00934705Set 9
2012-05-152p629w
From: "Alice Jacobs"
To: "Denise Marston" ctl
Subject: IMDx Obtains CE-marking for GBS Assay for screening for neonatal infections
Date ... that IMDx has obtained CE-marking for a
test for Group B Streptococcus (GBS), the most common pathogen associated with life-threatening
infections in newborns, including sepsis, meningitis, and pneumonia ... proud to add GBS to our
expanding infectious disease testing portfolio, which includes tests hospital-acquired infections including
C. difficile and vancomycin-resistant enterococci.
My best,
Alice
IntelligentMDx Announces
https://www.justice.gov/epstein/files/DataSet%209/EFTA00934705.pdf
EFTA01382663Set 10
2014-12-311p651w
value of goodwill was $17.0 billion, of which $14.3 billion was related to our GBS reporting
unit. As of June 30, 2015, the most recent impairment analysis date, the fair ... reporting units substantially exceeded their carrying value
with the exception of our GBS reporting unit. Our GBS reporting unit's carrying value exceeded fair value by 17%. Examples of events ... underlying key assumptions and ultimately impact the estimated fair value
of the aforementioned GBS reporting unit may include such items as the following:
Global economic, political, and other conditions
https://www.justice.gov/epstein/files/DataSet%2010/EFTA01382663.pdf
often makes us an attractive partner for established and emerging commerce solution providers.
For GBS, we believe we have the industry's largest network of bank partnerships for merchant acquiring ... smaller financial institutions through GSPs.
For NSS, we leverage the distribution platforms of GBS and GFS, and also distribute through a direct sales force.
Our Transformation
In 2013, we began
https://www.justice.gov/epstein/files/DataSet%2010/EFTA01382669.pdf
EFTA00614609Set 9
2011-01-201p379w
following
infectious organisms. Clostridium difficile, Vancomycin-Resistance Enterococci (VRE), Group B
Streptococci (GBS), Influenza A/Influenza B (INFA/B), and Herpes Simplex Virus 1 and 2 (HSV
1/2). In addition, two additional
https://www.justice.gov/epstein/files/DataSet%209/EFTA00614609.pdf
EFTA00902109Set 9
2011-01-213p622w
following infectious organisms, Clostridium difficile, Vancomycin-
Resistance Enterococci (VRE), Group B Streptococci (GBS), Influenza A/Influenza B (INFA/B), and Herpes Simplex
Virus 1 and 2 (HSV 1/2). In addition, two additional
https://www.justice.gov/epstein/files/DataSet%209/EFTA00902109.pdf
EFTA00640072Set 9
2011-01-202p505w
following infectious organisms, Clostridium difficile, Vancomycin-Resistance Enterococci
(VRE), Group B Streptococci (GBS), Influenza A/Influenza B (INFA/B), and Herpes Simplex Virus 1 and 2 (HSV 1/2). In
addition, two additional
https://www.justice.gov/epstein/files/DataSet%209/EFTA00640072.pdf
EFTA00648481Set 9
2011-01-212p669w
following infectious organisms, Clostridium difficile, Vancomycin-Resistance Enterococci
(VRE), Group B Streptococci (GBS), Influenza A/Influenza B (INFA/B), and Herpes Simplex Virus 1 and 2 (HSV 1/2). In
addition, two additional
https://www.justice.gov/epstein/files/DataSet%209/EFTA00648481.pdf